250 related articles for article (PubMed ID: 31885955)
1. Immunotherapy- (Blinatumomab-) Related Lineage Switch of
He RR; Nayer Z; Hogan M; Cuevo RS; Woodward K; Heyer D; Curtis CA; Peterson JF
Case Rep Hematol; 2019; 2019():7394619. PubMed ID: 31885955
[TBL] [Abstract][Full Text] [Related]
2. Lineage switch of KMT2A-rearranged adult B-lineage acute lymphoblastic leukemia following bispecific T-cell engager and monoclonal antibody therapy.
Wu JR; Shih PC; Li C; Chao HL; Wang HC; Chiang YM; Liu YJ; Hsu SC; Yao CY; Chen LH; Lin CC; Tien HF; Chou WC
J Hematop; 2023 Jun; 16(2):103-109. PubMed ID: 38175441
[TBL] [Abstract][Full Text] [Related]
3. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23);
Du J; Chisholm KM; Tsuchiya K; Leger K; Lee BM; Rutledge JC; Paschal CR; Summers C; Xu M
Pediatr Dev Pathol; 2021; 24(4):378-382. PubMed ID: 33749383
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a
Brethon B; Lainey E; Caye-Eude A; Grain A; Fenneteau O; Yakouben K; Roupret-Serzec J; Le Mouel L; Cavé H; Baruchel A
Front Oncol; 2021; 11():637951. PubMed ID: 33718232
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
[TBL] [Abstract][Full Text] [Related]
6. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Zoghbi A; Zur Stadt U; Winkler B; Müller I; Escherich G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453885
[TBL] [Abstract][Full Text] [Related]
7. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
Rayes A; McMasters RL; O'Brien MM
Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
[TBL] [Abstract][Full Text] [Related]
8. Expanding diagnostic criteria: Multiorgan T-Cell/myeloid mixed phenotype acute leukemia with t(v;11q23)
Syed S; Song A; Hussaini M
Leuk Res Rep; 2022; 17():100306. PubMed ID: 35356416
[TBL] [Abstract][Full Text] [Related]
9. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
10. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch.
Nakajima K; Kubota H; Kato I; Isobe K; Ueno H; Kozuki K; Tanaka K; Kawabata N; Mikami T; Tamefusa K; Nishiuchi R; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
Cancer Sci; 2022 Jul; 113(7):2472-2476. PubMed ID: 35467057
[TBL] [Abstract][Full Text] [Related]
11. Updates in
Górecki M; Kozioł I; Kopystecka A; Budzyńska J; Zawitkowska J; Lejman M
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979800
[TBL] [Abstract][Full Text] [Related]
12. Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
Bełdzińska-Gądek K; Zarzycka E; Pastuszak K; Borman K; Lewandowski K; Zaucha JM; Prejzner W
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38775354
[TBL] [Abstract][Full Text] [Related]
13. Leukemia With
Lin N; Yan X; Cai D; Wang L
Front Oncol; 2021; 11():709036. PubMed ID: 34395283
[TBL] [Abstract][Full Text] [Related]
14. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
[No Abstract] [Full Text] [Related]
15. Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab.
Abdo Y; Gibson GD; Jain SP; Milner CP; Hilal T
Cureus; 2023 Jun; 15(6):e40661. PubMed ID: 37485162
[TBL] [Abstract][Full Text] [Related]
16. Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.
Schneider P; Crump NT; Arentsen-Peters STCJM; Smith AL; Hagelaar R; Adriaanse FRS; Bos RS; de Jong A; Nierkens S; Koopmans B; Milne TA; Pieters R; Stam RW
Exp Hematol Oncol; 2023 Sep; 12(1):81. PubMed ID: 37740239
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
18. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.
Tretti Parenzan C; Molin AD; Longo G; Gaffo E; Buratin A; Cani A; Boldrin E; Serafin V; Guglielmelli P; Vannucchi AM; Cazzaniga G; Biondi A; Locatelli F; Meyer LH; Buldini B; Te Kronnie G; Bresolin S; Bortoluzzi S
Blood Adv; 2024 Mar; 8(5):1305-1319. PubMed ID: 38029383
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
20. Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.
Khabirova E; Jardine L; Coorens THH; Webb S; Treger TD; Engelbert J; Porter T; Prigmore E; Collord G; Piapi A; Teichmann SA; Inglott S; Williams O; Heidenreich O; Young MD; Straathof K; Bomken S; Bartram J; Haniffa M; Behjati S
Nat Med; 2022 Apr; 28(4):743-751. PubMed ID: 35288693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
